Blood-based mrd test for cancer recurrence can generate cost savings in colorectal cancer treatment, finds study in jama health forum

Circulating tumor dna (ctdna) testing for minimal residual disease (mrd) can reduce costs by up to 21% across health plan populations when half of eligible patients with stage ii colorectal cancer are tested for treatment decisions secaucus, n.j. and baltimore , may 31, 2024 /prnewswire/ -- a blood test could help reduce costs for health plans by reliably identifying patients who might be able to safely forgo chemotherapy after surgery for stage ii colorectal cancer, according to a study published today in jama health forum, a member of the jama network.
DGX Ratings Summary
DGX Quant Ranking